The curative effect of the associated cell transplantation on the rabbit myocardial infarction

Abstract

Inducing Mesenchymal stem cells to differentiate into cardiomyocycte-like cells and endothelial progenitor cells orientedly and evaluating the curative effect of the associated cell transplantation on the rabbit myocardial infarction (MI). Methods: Mesenchymal stem cells (MSCs) were isolated from the bone marrow of 24 rabbits and cultured in special cell culture medium containing 5-azacytidine (5-AZA), endothelial cell growth supplements (ECGS), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BFGF) respectively. The cell transplantation was performed 2 weeks after MI. Rabbits were divided into control group, cardiomyocytes-like cell group, endothelial progenitor cell group and combination group. We used the echocardiography to measure the heart function 2 to 4 weeks after MI, TTC to measure the area of the infarction, flow cytometry to estimate the cell apoptosis. Results: After induced, MSCs were differentiated orientedly into cardiomyocycte-like cells (CLCs) and endothelial progenitor cells (EPCs). CLCs became greater and had a “stick” or “ball” shape. Transmisson electron microscopy showed that the cells had oval nuclei positioned in the central part and well organized myofilaments, atrial granules and mitochomdrion. RT-PCR showed the expression of the atrial natriuretic polypeptide, phospholamban and myosin heavy chain in CLCs. EPCs formed confluent one-celled layer which showed a cobblestone shape by phase-contrast microscope. The expression of CD133 in EPCs was much at first and then descended gradually. Compared with the control group, cell transplantation could improve the heart function, reduce the size of MI, decrease the left ventricular end systole diameter and end diastolic diameter, suppressed cell apoptosis. The curative effect of cell transplantation was better in the associated-cell group than in the single-cell transplantation group (LVEF: 32.49% ± 1.29% vs 53.22% ± 2.13% vs 56.91% ± 2.04% vs 62.61% ± 2.37%, P < 0.05; LVESD: 1.23 ± 0.02 vs 0.98 ± 0.04 vs 0.98 ± 0.12 vs 1.11 ± 0.03, P < 0.05; LVEDD: 1.53 ± 0.13 vs 1.24 ± 0.02 vs 1.21 ± 0.09 vs 1.01 ± 0.01, P < 0.05; the area of infarction: 35.17% ± 0.98% vs 28.61% ± 1.24% vs 29.73% ± 2.11% vs 22.82% ± 3.12%, P < 0.05; apotosis: 8.6% ± 0.94% vs 6.94% ± 0.59% vs 6.4% ± 0.27% vs 4.63% ± 0.74%, P < 0.05). Conclusions: This study showed that MSCs can differentiate into CLCs and EPCs in the given conditions and the associated cell transplantation is better than the single cell transplantation to treat MI.

Share and Cite:

Fang, Z. , Zhou, C. , Zheng, X. , Liu, B. , Chen, L. , Shen, C. , Liu, P. and Huang, Y. (2013) The curative effect of the associated cell transplantation on the rabbit myocardial infarction. Stem Cell Discovery, 3, 203-210. doi: 10.4236/scd.2013.34025.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Flynn, A., Chen, X., O’Connell, E., et al. ( 2012) A comparison of the efficacy of transplantation of bone marrowderived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction. Stem Cell Research & Therapy, 3, 36-44. http://dx.doi.org/ 10.1186/scrt127
[2] Zeinaloo, A., Zanjani, K.S., Bagheri, M., et al. (2011) Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatric Transplantation, 15, E183-E186. http://dx.doi.org/10.1111/j.1399-3046.2010.01366.x
[3] Maureira, P., Marie, P.Y., Yu, F., et al. (2012) Repairing chronic myocardial infarction with autologous mesenchymal stem cells engineered tissue in rat promotes angiogenesis and limits ventricular remodeling. Journal of Biomedical Science, 19, 93-99. http://dx.doi.org/10.1186/1423-0127-19-93
[4] Kim, S.W., Lee, D.W., Yu, L.H., et al. (2012) Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model. Cardiovascular Research, 95, 495-506. http://dx.doi.org/10.1093/cvr/cvs224
[5] Kim, S.W., Lee, D.W., Yu, L.H., et al. (2012) Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model. Cardiovascular Research, 95, 495-506. http://dx.doi.org/10.1093/cvr/cvs224
[6] Chi, N.H., Yang, M.C., Chung, T., et al. (2012) Cardiac repair achieved by bone marrow mesenchymal stem cells/ silk fibroin/hyaluronic acid patches in a rat of myocardial infarction model. Biomaterials, 33, 5541-5551. http://dx.doi.org/10.1016/j.biomaterials.2012.04.030
[7] Wang, T., Sun, S., Wan, Z., et al. (2012) Effects of bone marrow mesenchymal stem cells in a rat model of myocardial infarction. Resuscitation, 83, 1391-1396. http://dx.doi.org/10.1016/ j.resuscitation.2012.02.033
[8] Zheng, S.X., Weng, Y., Zhou, C., et al. (2012) Comparison of cardiac stem cells and mesenchymal stem cells transplantation on the cardiac electrophysiology in rats with myocardial infarction. Stem Cell Reviews, 4, 1-11.
[9] Otto Beitnes, J., Oie, E., Shahdadfar, A., et al. (2012) Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant, 21, 1697-1709. http://dx.doi.org/10.3727/0963689 11X627462
[10] Du, Y.Y., Yao, R., Hu, X.Q., et al. (2011) Dural modulation effects of mesenchymal stem cells implantation on myocardial collagen remodeling in a rat model of myocardial infarction. Chinese Journal of Cardiovascular Diseases, 39, 840-846.
[11] Xie, X., Sun, A., Zhu, W., et al. (2012) Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. Tohoku Journal of Experimental Medicine, 226, 29-36. http://dx.doi.org/10.1620/tjem.226.29
[12] Shi, B., Liu, Z.J., Zhao, R.Z., et al. (2011) Effect of mesenchymal stem cells on cardiac function and restenosis of injured artery after myocardial infarction. National Medical Journal of China, 91, 2269-2273.
[13] Mishra, P.K. (2008) Bone marrow-derived mesenchymal stem cells for treatment of heart failure: Is it all paracrine actions and immunomodulation? Journal of Cardiovascular Medicine, 9, 122-128. http://dx.doi.org/10.2459/JCM. 0b013e32820588f0
[14] Du, Y.Y., Yao, R., Pu, S., et al. (2012) Mesenchymal stem cells implantation increases the myofibroblasts congergating in infarct region in a rat model of myocardial infarction. Chinese Journal of Cardiovascular Diseases, 40, 1045-1050.
[15] Wen, Z., Zheng, S., Zhou, C., et al. (2012) Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators. Journal of Cellular and Molecular Medicine, 16, 657-671. http://dx.doi.org/10.1111/j.1582-4934.2011.01471.x
[16] Nayan, M., Paul, A., Chen, G., et al. (2011) Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: In vitro and in vivo investigation. Journal of Tissue Engineering, 11, 211-223.
[17] Jin, J., Zhao, Y., Tan, X., et al. (2011) An improved transplantation strategy for mouse mesenchymal stem cells in an acute myocardial infarction model. PLoS One, 6, e21005. http://dx.doi.org/10.1371/ journal. pone.0021005
[18] Vassalli, G. and Moccetti, T. (2011) Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Medical Weekly, 141, w13209.
[19] Carlson, S., Trial, J., Soeller, C., et al. (2011) Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. Cardiovascular Research, 91, 99-107. http://dx.doi.org/ 10.1093/cvr/cvr061
[20] Wen, Z., Zheng, S., Zhou, C., et al. (2011) Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. Journal of Cellular and Molecular Medicine, 15, 1032-1043. http://dx.doi.org/10.1111/j.1582-4934. 2010.01255.x
[21] Arminán, A., Gandía, C., García-Verdugo, J.M., et al. (2010) Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. Journal of the American College of Cardiology, 55, 2244-2053. http://dx.doi.org/10.1016/j.jacc.2009.08.092
[22] Hare, J.M., Traverse, J.H., Henry, T.D., et al. (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277-2086. http://dx.doi.org/10.1016/j.jacc. 2009.06.055
[23] Li, Z., Guo, J., Chang, Q., et al. (2009) Paracrine role for mesenchymal stem cells in acute myocardial infarction. Biological & Pharmaceutical Bulletin, 32, 1343-1346. http://dx.doi.org/10.1248/ bpb.32.1343
[24] Mias, C., Lairez, O., Trouche, E., et al. (2009) Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells, 27, 2734-2743. http://dx.doi.org/10.1002/stem.169
[25] Grauss, R.W., Winter, E.M., van Tuyn, J., et al. (2007) Mesenchymal stem cells from ischemic heart disease patients improve left ventricular function after acute myocardial infarction. American Journal of Physiology, Heart and Circulatory Physiology, 293, H2438-H2447. http://dx.doi.org/10.1152/ ajpheart. 00365.2007
[26] Berger, S., Aronson, D., Lavie, P., et al. (2013) Endothelial progenitor cells in acute myocardial infarction and sleep-disordered breathing. American Journal of Respiratory and Critical Care Medicine, 187, 90-98. http://dx.doi.org/10.1164/rccm.201206-1144OC
[27] Kuliczkowski, W., Derzhko, R., Prajs, I., et al. (2012) Endothelial progenitor cells and left ventricle function in patients with acute myocardial infarction: Potential therapeutic considertions. American Journal of Therapeutics, 19, 44-50. http://dx.doi.org/10.1097/MJT.0b013e3181e0cab3
[28] Schuh, A., Liehn, E.A., Sasse, A., et al. (2010) Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Research in Cardiology, 103, 69-77. http://dx.doi.org/10.1007/s00395-007-0685-9
[29] Lev, E.I., Kleiman, N.S., Birnbaum, Y., et al. (2005) Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. Journal of Vascular Research, 42, 408-414. http://dx.doi.org/10.1159/000087370
[30] Mitchell, A.J., Sabondjian, E., Blackwood, K.J., et al. (2013) Comparison of the myocardial clearance of endothelial progenitor cells injected early versus late into reperfused or sustained occlusion myocardial infarction. International Journal of Cardiovascular Imaging, 29, 497-504. http://dx.doi.org/10.1007/ s10554-012-0086-5
[31] Jung, C., Florvaag, A., Oberle, V., et al. (2012) Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. Journal of the Renin-Angiotensin-Aldosterone System, 13, 401-406. http://dx.doi.org/10.1177/1470320312447650

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.